Home > Advanced Breast Cancer

Advanced Breast Cancer

Watch interviews and expert perspectives covering the latest findings for treating HR+/HER2 Advanced Breast Cancer using CDK4/6 hinibitors from key cancer congresses throughout 2019.

Curriculum Activities

Breast Cancer
touchCONGRESS Webinar
HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the SABCS 2019?
Dr Fátima Cardoso Watch Time: 24 mins

Watch leading breast cancer expert, Dr Fátima Cardoso, review the latest findings for treating HR+/HER2- advanced breast cancer using CDK4/6 inhibitors, from the SABCS, Texas, US, 10–14 December 2019.

Learning objectives
Learning Objectives
  • Describe the role of CDK4/6 inhibitors in the context of the current and evolving treatment landscape for patients with HR+/HER2- advanced breast cancer
  • Evaluate the importance of selecting the optimal treatment based on the individual patient, and the challenges around subsequent sequencing of therapy
  • Summarize the importance of managing the safety profiles of CDK4/6 inhibitor therapy, and recognize the significance of the multidisciplinary team in optimizing patient outcomes and maintaining on-treatment benefits
Breast Cancer
touchCONGRESS Expert Interviews
HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the SABCS 2019?
Dr Eva Ciruelos, Prof. George Sledge, Dr Norikazu Masuda, Dr Fátima Cardoso, Prof. Frédérique Penault-Llorca, Prof. Dr Jens Huober Watch Time: 46 mins

Watch leading breast cancer experts from Europe, the US and Japan discuss the latest data presented at the SABCS, Texas, US, 10–14 December 2019, and consider what the findings may mean for global and regional clinical practice.

Learning objectives
Learning Objectives
  • Describe the role of CDK4/6 inhibitors in the context of the current and evolving treatment landscape for patients with HR+/HER2- advanced breast cancer
  • Evaluate the importance of selecting the optimal treatment based on the individual patient, and the challenges around subsequent sequencing of therapy
  • Summarize the importance of managing the safety profiles of CDK4/6 inhibitor therapy, and recognize the significance of the multidisciplinary team in optimizing patient outcomes and maintaining on-treatment benefits
Breast Cancer
touchCONGRESS Webinar
HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the ESMO 2019?
Dr Olivier Trédan Watch Time: 23 mins

Watch leading breast cancer expert, Dr Olivier Trédan, review the latest findings for treating HR+/HER2- advanced breast cancer using CDK4/6 inhibitors, from the ESMO Congress in Barcelona, Spain, 27 September–1 October 2019.

Learning objectives
Learning Objectives
  • Describe the role of CDK4/6 inhibitors in the context of the current and evolving treatment landscape for patients with HR+/HER2- advanced breast cancer
  • Evaluate the importance of selecting the optimal treatment based on the individual patient, and the challenges around subsequent sequencing of therapy
  • Summarize the importance of managing the safety profiles of CDK4/6 inhibitor therapy, and recognize the significance of the multidisciplinary team in optimizing patient outcomes and maintaining on-treatment benefits
Breast Cancer
touchCONGRESS Expert Interviews
HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the ESMO 2019?
Dr Judy King, Dr Emilio Alba, Prof. Masahiro Takada, Dr. Oliver Trédan, Prof. Wolfgang Janni, Prof. Valentina Guarneri Watch Time: 42 mins

Watch leading breast cancer experts from Europe and Japan discuss the latest data presented at the ESMO Congress in Barcelona, Spain, 27 September–1 October 2019, and consider what the findings may mean for global and regional clinical practice.

Learning objectives
Learning Objectives
  • Describe the role of CDK4/6 inhibitors in the context of the current and evolving treatment landscape for patients with HR+/HER2- advanced breast cancer
  • Evaluate the importance of selecting the optimal treatment based on the individual patient, and the challenges around subsequent sequencing of therapy
  • Summarize the importance of managing the safety profiles of CDK4/6 inhibitor therapy, and recognize the significance of the multidisciplinary team in optimizing patient outcomes and maintaining on-treatment benefits
Breast Cancer
touchCONGRESS Webinar
HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the ASCO Meeting 2019?
Dr Joyce A. O'Shaughnessy Watch Time: 37 mins

Watch internationally regarded breast cancer expert, Dr. Joyce A. O’Shaughnessy, discuss the latest developments in CDK4/6 inhibitors for advanced breast cancer presented at the ASCO Annual Meeting in Chicago, United States, 31 May–4 June 2019.

Learning objectives
Learning Objectives
  • Describe the role of CDK4/6 inhibitors in the context of the current and evolving treatment landscape for patients with HR+/HER2- advanced breast cancer
  • Evaluate the importance of selecting the optimal treatment based on the individual patient, and the challenges around subsequent sequencing of therapy
  • Summarize the importance of managing the safety profiles of CDK4/6 inhibitor therapy, and recognize the significance of the multidisciplinary team in optimizing patient outcomes and maintaining on-treatment benefits
Breast Cancer
touchCONGRESS Expert Interviews
HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the ASCO Meeting 2019?
Dr Véronique Diéras, Prof. Sherko Kümme, Prof. Dr Patrick Neven, Prof. Joohyuk Sohn, Dr Joyce A. O'Shaughnessy, Prof. Michelino de Laurentiis Watch Time: 52 mins

Watch leading breast cancer experts from Europe, United States and South Korea discuss the latest data presented at the ASCO Annual Meeting in Chicago, United States, 31 May–4 June 2019, and consider what the findings may mean for global and regional clinical practice.

Learning objectives
Learning Objectives
  • Describe the role of CDK4/6 inhibitors in the context of the current and evolving treatment landscape for patients with HR+/HER2- advanced breast cancer
  • Evaluate the importance of selecting the optimal treatment based on the individual patient, and the challenges around subsequent sequencing of therapy
  • Summarize the importance of managing the safety profiles of CDK4/6 inhibitor therapy, and recognize the significance of the multidisciplinary team in optimizing patient outcomes and maintaining on-treatment benefits
Breast Cancer
touchCONGRESS Webinar
HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the ESMO Breast Cancer Congress 2019?
Prof. Sibylle Loibi Watch Time: 28 mins

Watch internationally renowned expert, Professor Sybille Loibl, discuss the latest developments in CDK4/6 inhibitors for advanced breast cancer presented at the ESMO Breast Cancer Congress in Berlin, Germany, 2–4 May 2019.

Learning objectives
Learning Objectives
  • Describe the role of CDK4/6 inhibitors in the context of the current and evolving treatment landscape for patients with HR+/HER2- advanced breast cancer
  • Evaluate the importance of selecting the optimal treatment based on the individual patient, and the challenges around subsequent sequencing of therapy
  • Summarize the importance of managing the safety profiles of CDK4/6 inhibitor therapy, and recognize the significance of the multidisciplinary team in optimizing patient outcomes and maintaining on-treatment benefits
Breast Cancer
touchCONGRESS Expert Interviews
HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the ESMO Breast Cancer Congress 2019?
Prof. Gabriel Hortobagyi, Prof. Joan Albanell, Prof. Sibylle Loibl, Prof. Mario Campone, Prof. Giuseppe Curigliano, Prof. Stephen Johnston Watch Time: 70 mins

Watch leading breast cancer experts from Europe and the United States discuss the latest data presented at the ESMO Breast Cancer Congress in Berlin, Germany, 2–4 May 2019, and consider what the findings may mean for global and regional clinical practice.

Learning objectives
Learning Objectives
  • Describe the role of CDK4/6 inhibitors in the context of the current and evolving treatment landscape for patients with HR+/HER2- advanced breast cancer
  • Evaluate the importance of selecting the optimal treatment based on the individual patient, and the challenges around subsequent sequencing of therapy
  • Summarize the importance of managing the safety profiles of CDK4/6 inhibitor therapy, and recognize the significance of the multidisciplinary team in optimizing patient outcomes and maintaining on-treatment benefits

Other Curriculum Activities

Learn more with a series of activities which are linked and developed as a curriculum

Lung Cancer
touchCURRICULUM
EGFR + NSCLC

Watch interviews and expert perspectives covering the latest developments in EGFR TKIs for patients with NSCLC from the ESMO Congress and ESMO Asia Congress 2019.

Lung Cancer
Curriculum Inclusions:
  • Recall recent data for 3rd-generation EGFR TKIs in first-line EGFR+ NSCLC and describe real-world evidence
  • Describe treatment sequencing and the paradigm for therapy of EGFR+ NSCLC
  • Discuss issues related to biomarker testing, including timing and access
IME
CME activities are developed by touchIME for touchONCOLOGY.

Our education resources are developed in collaboration with our well established peer-reviewed medical journals, our Editorial Board members and partnerships with major medical societies, with a clear commitment to high-quality independent education.

Copied to clipboard!
accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar